Author: Oannes Biotech


  • Epigenetic CRISPR Editing: A Breakthrough in Gene Therapy Without DNA Cleavage

    The annals of molecular biology have long documented a fundamental paradox regarding DNA methylation: whether the attachment of methyl groups to cytosine-phosphate-guanine dinucleotides represents merely a passive consequence of gene silencing or constitutes the primary mechanism through which transcriptional repression is actively maintained. This decades-old debate has now been resolved through elegant experimental work published…

  • FDA Approves YARTEMLEA: A Breakthrough in Complement Pathway Inhibition

    The final days of 2025 witnessed a significant milestone in transplantation medicine, as the Food and Drug Administration granted approval to YARTEMLEA (narsoplimab-wuug) on December 24th—the first and only therapy indicated for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). This approval represents more than a mere regulatory achievement; it marks the culmination of decades of…

  • Biomimetic Polymer Chemistry: Engineering Programmable Degradation in Synthetic Plastics Through Structural Principles Derived from Natural Macromolecules

    The distinction between biological and synthetic polymers has long intrigued materials scientists: natural macromolecules such as deoxyribonucleic acid, ribonucleic acid, and proteins undergo controlled degradation, while petrochemical-derived plastics persist in terrestrial and aquatic ecosystems for decades. Recent work published in Nature Chemistry in November 2024 by investigators at Rutgers University demonstrates that incorporation of conformationally…

  • Decoding Nature’s Hidden Arsenal: The Enzymatic Pathway to Mitraphylline

    The ancient relationship between humanity and medicinal plants stretches back millennia, from the Hippocratic texts that first documented systematic botanical therapeutics in the 5th century BC to the discovery of modern pharmaceutical landmarks such as aspirin from willow bark and paclitaxel from Pacific yew. Yet for all our historical reliance upon nature’s pharmacopeia, the molecular…

  • Untitled post 1832

    Base-Edited CAR T-Cell Therapy Achieves Remission in Refractory T-Cell Leukemia The therapeutic armamentarium against hematological malignancies has been substantially enriched through the clinical implementation of BE-CAR7, a pioneering base-edited chimeric antigen receptor T-cell therapy targeting T-cell acute lymphoblastic leukemia. Announced this December by investigators at University College London and Great Ormond Street Hospital, this therapeutic…

  • Resurrecting Ancient Transcriptomes: RNA Sequencing from Late Pleistocene Woolly Mammoths

    The preservation of biological macromolecules within geological strata has long captivated investigators seeking to comprehend extinct organisms. Whilst ancient DNA analysis has achieved remarkable temporal depth—extending beyond one million years—the recovery of ribonucleic acid from paleontological specimens has remained constrained by the presumed chemical lability of this molecule. RNA degradation typically proceeds rapidly following organismal…

  • Aptamers and Senescent Cells: A Novel Molecular Approach to the Biology of Aging

    The investigation of cellular senescence—that biological phenomenon wherein cells cease proliferation yet persist within tissue architecture—has recently witnessed a methodological advance of considerable significance. Researchers at Mayo Clinic, reporting in the journal Aging Cell on December 14, 2025, have successfully employed DNA aptamers to selectively identify and label senescent cells, commonly referred to as “zombie…

  • Revealing the Hidden Architecture of Chromatin: High-Resolution Imaging Illuminates DNA Compaction

    The organization of deoxyribonucleic acid within the cellular nucleus presents one of the most remarkable engineering challenges in biology. Within each human cell, approximately two meters of genetic material must be compacted into a nucleus whose diameter measures merely one-hundredth that of a human hair, yet this compression must preserve complete accessibility to the genetic…

  • FDA Approves First Therapy for High-Risk Smoldering Multiple Myeloma: Daratumumab Marks Paradigm Shift in Preemptive Oncological Intervention

    Throughout the chronicles of hematologic oncology, from the empirical observations of plasma cell dyscrasias documented in nineteenth-century medical literature to the molecular sophistication of contemporary immunotherapy, the therapeutic paradigm has remained fundamentally reactive—intervening only upon manifestation of overt malignancy. Where once clinicians maintained vigilant surveillance of precancerous states through expectant observation, the field now confronts…

  • Resurrecting an Ancient Enzyme: CRISPR Technology Reactivates Lost Gene to Combat Gout and Metabolic Disease

    The evolutionary loss of metabolic capabilities sometimes leaves modern humans vulnerable to conditions that our distant ancestors may never have encountered. Such is the case with hyperuricemia, the pathological accumulation of uric acid in human tissues that underlies gout and several related metabolic disorders. Recent investigations at Georgia State University have now employed CRISPR-Cas9 gene-editing…